HC Wainwright & Co. Maintains Buy on BridgeBio Pharma, Raises Price Target to $120

Benzinga Newsdesk www.benzinga.com Positive 80.8%

Neg 0% Neu 0% Pos 80.8%

HC Wainwright & Co. analyst Raghuram Selvaraju maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $110 to $120.